{"id":995392,"date":"2026-08-14T08:08:38","date_gmt":"2026-08-14T12:08:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign\/"},"modified":"2026-08-14T08:08:38","modified_gmt":"2026-08-14T12:08:38","slug":"allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign\/","title":{"rendered":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign"},"content":{"rendered":"
\n

\u00a0 \u00a0
– Completed quarter with $26.9 million in cash and restricted cash<\/i><\/p>\n

\n – Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP<\/i>
\n
\n \u00ae<\/i>
\n <\/sup>
\n companion diagnostic into 2042 <\/i>\n <\/p>\n

\n – AACR 2026 data linked higher stenoparib DRP<\/i>
\n
\n \u00ae<\/i>
\n <\/sup>
\n scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP<\/i>
\n
\n \u00ae<\/i>
\n <\/sup>
\n -guided patient selection<\/i>\n <\/p>\n

\n – Obtained CLIA certification for its in-house laboratory, enabling full control of DRP<\/i>
\n
\n \u00ae<\/i>
\n <\/sup>
\n testing to accelerate and support U.S. clinical trials
<\/i>
\n \n <\/p>\n

\n TARPON SPRINGS, Fla., <\/b>AUGUST 14, 2026 \u2013 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)\u2014a differentiated, dual PARP and WNT pathway inhibitor\u2014
today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2026.<\/p>\n

\u201cThe second quarter was a highly productive period for Allarity. During the quarter, the USPTO granted the key U.S. patent covering our stenoparib-specific DRP\u00ae companion diagnostic, providing exclusivity to develop stenoparib with its DRP\u00ae into April 2042. This establishes a critical, long-term intellectual property foundation for stenoparib development and commercialization and reinforces our confidence in the long-term potential of our approach to pairing anticancer therapeutics with drug-specific companion diagnostics,\u201d said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics.<\/p>\n

\u201cSubsequent to quarter-end, we also successfully completed our manufacturing campaign for stenoparib, securing drug supply in accordance with the more stringent standards required for late-stage clinical development. Completion of this campaign represents an important step as we prepare for a pivotal, registrational trial. We have also secured CLIA certification for our in-house laboratory, enabling us to do all of the necessary testing for the DRP\u00ae in-house, which will further secure our ability to control and accelerate the advance of stenoparib toward FDA approval. I am particularly proud of these accomplishments as they position the company to drive stenoparib forward as rapidly as possible. Together with the presentation of our promising, durable Phase 2 clinical benefit data in advanced ovarian cancer patients at leading international oncology conferences, these achievements further strengthen the foundation for accelerating stenoparib toward FDA approval. Finally, I am pleased that we ended the quarter with almost $27 million in cash and restricted cash, providing us with the financial resources to continue the important work of advancing stenoparib.\u201d<\/p>\n

\n Clinical and Drug Development Progress<\/b>\n <\/p>\n